Case report: Senescence as mechanism of resistance to Pembrolizumab in a Lymphoma patient who failed CD19-Targeted CAR-T cell therapy

BACKGROUND: T cells engineered to target CD19 antigen on neoplastic B cells represent the most striking example of CAR-T cell therapy. The success rate of this therapy is affected by several limitations: target antigen loss, and/or acquisition of a senescent/exhausted phenotype by CAR and non-CAR T...

Descripción completa

Detalles Bibliográficos
Autores principales: De Matteis, Serena, Casadei, Beatrice, Lolli, Ginevra, Dicataldo, Michele, Barbato, Francesco, Dan, Elisa, Paccagnella, Andrea, Sinigaglia, Barbara, Bertuzzi, Clara, Arcari, Annalisa, Zazzeroni, Luca, Bernuzzi, Patrizia, Laprovitera, Noemi, Storci, Gianluca, Bertuccio, Salvatore Nicola, Ferracin, Manuela, Bonafè, Massimiliano, Zinzani, Pier Luigi, Bonifazi, Francesca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9584643/
https://www.ncbi.nlm.nih.gov/pubmed/36275688
http://dx.doi.org/10.3389/fimmu.2022.994731

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9584643/
https://www.ncbi.nlm.nih.gov/pubmed/36275688
http://dx.doi.org/10.3389/fimmu.2022.994731

Ejemplares similares